Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib – results from a non-interventional multi-center study

BACKGROUND: Gemcitabine/erlotinib treatment offers limited benefit in unselected patients with pancreatic ductal adenocarcinoma (PDAC). Development of skin rash has been associated with favorable outcomes in patients treated with gemcitabine/erlotinib. This study aimed to extend knowledge on the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Westphalen, C. Benedikt, Kukiolka, Tobias, Garlipp, Benjamin, Hahn, Lars, Fuchs, Martin, Malfertheiner, Peter, Reiser, Marcel, Kütting, Fabian, Heinemann, Volker, Beringer, Andreas, Waldschmidt, Dirk T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041266/
https://www.ncbi.nlm.nih.gov/pubmed/32093649
http://dx.doi.org/10.1186/s12885-020-6636-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041266/
https://www.ncbi.nlm.nih.gov/pubmed/32093649
http://dx.doi.org/10.1186/s12885-020-6636-7

Ejemplares similares